###begin article-title 0
###xml 37 42 <span type="species:ncbi:9606">women</span>
Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy
###end article-title 0
###begin title 1
Background:
###end title 1
###begin p 2
###xml 368 376 <span type="species:ncbi:9606">patients</span>
Recurrent fetal loss (RPL) is one of the most common cause of sterility. Several studies identified thrombophilia as the principal cause of recurrent pregnancy loss. However, reported studies often do not evaluate other causes of miscarriages in their inclusion and exclusion criteria. So the aim of our study was to investigate the role of inherited thrombophilia in patients with RPL and without other causes of RPL.
###end p 2
###begin title 3
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods:
###end title 3
###begin p 4
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 249 257 <span type="species:ncbi:9606">patients</span>
###xml 345 350 <span type="species:ncbi:9606">women</span>
Patients with 2 or more first trimester abortion or with 1 or more late pregnancy loss were considered for this study. In order to evaluate the causes of RPL we looked for chromosomal, endocrine, chronic inflammatory, and infectious alterations. 90 patients affected by unexplained RPL were enrolled and tested for hemostatic alterations. These women were tested for inherited and/or acquired thrombophilia by MTHFR C677T gene polymorphism, factor V Leiden gene polymorphism, PTHRA20210G gene polymorphism, protein S deficiency, protein C deficiency, antithrombin III deficiency, lupus anticoagulant, and anticardiolipin antibodies Ig G and Ig M.
###end p 4
###begin title 5
Results:
###end title 5
###begin p 6
###xml 142 147 <span type="species:ncbi:9606">women</span>
###xml 189 194 <span type="species:ncbi:9606">women</span>
Acquired and/or inherited thrombophilia are strongly associated with RPL when other common causes of miscarriage were excluded. 78% of tested women showed hemostatic abnormalities. Several women with combined thrombophilic defects were also identified by our data.
###end p 6
###begin title 7
Conclusion:
###end title 7
###begin p 8
###xml 59 64 <span type="species:ncbi:9606">women</span>
###xml 146 151 <span type="species:ncbi:9606">women</span>
###xml 342 350 <span type="species:ncbi:9606">patients</span>
After a thorough evaluation of other causes of miscarriage women affected by RPL should be tested for thrombophilia. Our data demonstrated 78% of women with one or combined thrombophilic conditions. Differences with previous studies should be related to difference in the inclusion and exclusion criteria and ethnic background. Because these patients often also show a hypercoagulable state, it an antithrombotic treatment before and during pregnancy may improve their clinical outcome (ie, secondary prevention of miscarriage and primary thromboprophylaxis).
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 256 275 256 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12-btt-2-897">Di Micco et al 2004</xref>
###xml 206 211 <span type="species:ncbi:9606">women</span>
Recurrent fetal loss (RPL) is one of the most common causes of sterility. In a recent study we underlined the relevant role of d-dimer, as a marker of hypercoagulable state, in identifying thrombophilia in women affected by primary or secondary sterility (Di Micco et al 2004).
###end p 10
###begin p 11
###xml 8 28 8 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-btt-2-897">Brenner et al (1999)</xref>
###xml 218 237 218 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35-btt-2-897">Sanson et al (1996)</xref>
###xml 569 587 569 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-btt-2-897">Brenner et al 1999</xref>
###xml 589 604 589 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-btt-2-897">Carp et al 2002</xref>
###xml 606 622 606 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15-btt-2-897">Finan et al 2002</xref>
###xml 624 643 624 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16-btt-2-897">Grandone et al 1997</xref>
###xml 645 655 645 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17-btt-2-897">Greer 2003</xref>
###xml 657 678 657 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24-btt-2-897">Martinelli et al 2000</xref>
###xml 680 699 680 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27-btt-2-897">Pabinger et al 2000</xref>
###xml 701 721 701 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28-btt-2-897">Pickering et al 2001</xref>
###xml 723 741 723 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29-btt-2-897">Pihusch et al 2001</xref>
###xml 743 757 743 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30-btt-2-897">Rai et al 2001</xref>
###xml 759 787 759 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31-btt-2-897">Reznikoff-Etievan et al 2001</xref>
###xml 789 806 789 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41-btt-2-897">Younis et al 2001</xref>
###xml 95 100 <span type="species:ncbi:9606">women</span>
###xml 195 200 <span type="species:ncbi:9606">women</span>
###xml 330 335 <span type="species:ncbi:9606">women</span>
###xml 589 593 <span type="species:ncbi:7962">Carp</span>
In 1999 Brenner et al (1999) identified thrombophilia as a principal cause in more than 40% of women affected by RPL. Further studies underlined a pathogenetic role of inherited thrombophilia in women affected by RFL. Sanson et al (1996) reported an increased frequency of antithrombin III, protein C, and protein S deficiency in women with RPL, while several studies underlined the role of inherited thrombophilia (in particular related to factor V Leiden gene polymorphism and prothrombin A20210G gene polymorphism) in the pathophysiology of recurrent pregnacy loss (Brenner et al 1999; Carp et al 2002; Finan et al 2002; Grandone et al 1997; Greer 2003; Martinelli et al 2000; Pabinger et al 2000; Pickering et al 2001; Pihusch et al 2001; Rai et al 2001; Reznikoff-Etievan et al 2001; Younis et al 2001).
###end p 11
###begin p 12
###xml 350 367 350 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14-btt-2-897">Fatini et al 2000</xref>
###xml 369 386 369 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23-btt-2-897">Lissak et al 1999</xref>
###xml 388 404 388 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25-btt-2-897">Nelen et al 1997</xref>
###xml 406 424 406 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40-btt-2-897">Wouters et al 1993</xref>
###xml 100 105 <span type="species:ncbi:42554">tetra</span>
Yet increasing evidence is available on the relationship between hyperhomocysteinemia and methylene-tetra-hydrofolate reductase (MTHFR) C677T gene polymorphism and unexplained recurrent pregnancy loss. Several reports have described an association between early recurrent pregnancy loss and hyperhomocysteinemia and/or MTHFR C677T gene polymorphism (Fatini et al 2000; Lissak et al 1999; Nelen et al 1997; Wouters et al 1993).
###end p 12
###begin p 13
###xml 58 91 58 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13-btt-2-897">Dossenbach-Glaninger et al (2004)</xref>
###xml 321 346 321 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-btt-2-897">Asherson and Cervera 1994</xref>
###xml 348 370 348 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-btt-2-897">Chakrabarti et al 1999</xref>
###xml 372 386 372 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11-btt-2-897">Das et al 1991</xref>
###xml 388 408 388 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-btt-2-897">Higashino et al 1998</xref>
###xml 410 435 410 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20-btt-2-897">Infante-Rivard et al 1991</xref>
###xml 437 453 437 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26-btt-2-897">Noble et al 2005</xref>
###xml 558 578 558 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-btt-2-897">Braulke et al (1993)</xref>
###xml 655 673 655 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22-btt-2-897">Jones et al (2001)</xref>
###xml 1149 1165 1149 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10-btt-2-897">D&#8217;Uva et al 2005</xref>
###xml 736 741 <span type="species:ncbi:9606">women</span>
###xml 1111 1116 <span type="species:ncbi:9606">woman</span>
Acquired thrombophilia has also been associated with RPL. Dossenbach-Glaninger et al (2004) revealed that elevated maternal plasma levels of clotting factor VIII tend to be associated with an increased risk of RPL. Several studies have shown an association between RPL and primary or secondary antiphospholipid syndrome (Asherson and Cervera 1994; Chakrabarti et al 1999; Das et al 1991; Higashino et al 1998; Infante-Rivard et al 1991; Noble et al 2005). On this topic, a rare condition, acquired deficiency of clotting factor XII, has been described which Braulke et al (1993) identified for the first time a factor XII deficiency in RPL. Subsequently, Jones et al (2001) reported acquired factor XII deficiency in a subpopulation of women with antiphospholipid antibodies and RPL. Acquired clotting inhibitors, such as antibodies directed toward clotting factors, may induce an acquired clotting factors deficiency. In this field, we recently identified an unusual clinical presentation of antiphospholipid syndrome with clotting factor XII deficiency and the presence of antibodies to factor XII in a young woman with unexplained recurrent RPL (D'Uva et al 2005).
###end p 13
###begin p 14
###xml 202 210 <span type="species:ncbi:9606">patients</span>
However, reported studies often do not evaluate other causes of miscarriages in their inclusion and exclusion criteria. So the aim of our study was to investigate the role of inherited thrombophilia in patients with RPL after exclusion of other causes of RPL.
###end p 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods
###end title 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 16
###begin title 17
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient selection
###end title 17
###begin p 18
###xml 58 63 <span type="species:ncbi:9606">women</span>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
Starting from 1 January 2005, we selected 250 outpatients women referred to our Sterility Center for infertility owing to RPL. All patients with 2 or more first trimester abortions or with 1 or more late pregnancy loss were considered for this study. In order to evaluate the causes of RPL we looked for chromosomal alterations, endocrine diseases, chronic inflammatory, and infectious diseases.
###end p 18
###begin p 19
###xml 1090 1099 1090 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Chlamydia</italic>
###xml 1131 1140 1131 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Chlamydia</italic>
###xml 1216 1225 1216 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Chlamydia</italic>
###xml 1362 1369 1362 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1-btt-2-897">Table 1</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 631 639 <span type="species:ncbi:9606">patients</span>
###xml 1240 1248 <span type="species:ncbi:9606">patients</span>
###xml 1298 1303 <span type="species:ncbi:9606">women</span>
All patients underwent karyotype study in order to detect several chromosomal aberrations such as balanced translocations. The uterine cavity was evaluated anatomically by transvaginal ultrasound scan and hysterosalpingography and/or hysteroscopy in order to detect mullerian malformations or the presence of fibroids or polyps. Endocrinological assessment included screening for diabetes, hypothyroidism, hypopituitarism, hyperprolactinemia, luteal insufficiency, and polycystic ovarian syndrome (PCOS). Basal FSH, LH, and estradiol, and luteal phase progesterone, TSH, prolactin levels, and fasting glucose were evaluated in all patients. In addition, trans-vaginal USG and androgens levels were assessed to look for PCOS. Chronic inflammation owing to immunological disease such as erythematosus lupus, rheumatoid arthritis, and systemic sclerosis were also studied. Serum level of antinuclear antibodies (ANA), antimithocondrial antibodies (AMA), and smooth muscle cells antibodies (SMA), rheumatoid arthritis, and levels of C reactive protein were assessed. Infective disease owing to Chlamydia spp, was evaluated by specific Chlamydia assays, associated with serological levels of specific IgG and IgM against Chlamydia spp. Moreover patients affected by obesity were excluded, in particular women with body mass index > 27 were not enrolled in the study. Table 1 summarizes exclusion criteria.
###end p 19
###begin title 20
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient group
###end title 20
###begin p 21
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 81 86 <span type="species:ncbi:9606">women</span>
###xml 156 161 <span type="species:ncbi:42554">tetra</span>
After this screening we selected 115 patients affected by unexplained RPL. These women were tested for inherited and/or acquired thrombophilia by methylene-tetra-hydrofolate reductase (MTHFR) C677T gene polymorphism, factor V Leiden gene polymorphism, PTHRA20210G gene polymorphism, protein S deficiency, protein C deficiency, antithrombin III deficiency, lupus anticoagulant, and anticardiolipin antibodies Ig G and Ig M.
###end p 21
###begin title 22
Methods
###end title 22
###begin p 23
Whole blood samples were collected from all selected subjects in the study by venipuncture from antecubital vein in order to screen for possible involvement hemostasis alteration.
###end p 23
###begin title 24
First blood sample
###end title 24
###begin p 25
###xml 155 163 <span type="species:ncbi:9606">Patients</span>
A whole blood sample (5 mL) was collected in EDTA by venipuncture of antecubital vein. DNA was extracted using the "NUCLEON BACC" kit (Amershan, Germany). Patients were screened for the following mutations: Factor V G1691A gene polymorphism, A20210G gene polymorphism of the prothrombin, and C677T gene polymorphism of MTHFR using PCR amplification with specific primers and the Light Cycler apparatus (Roche, Italy).
###end p 25
###begin title 26
Second blood sample
###end title 26
###begin p 27
A second blood sample (5 mL) was collected in a Vacutainer tube containing 0.129 M sodium citrate; the ratio of anticoagulant to blood was 1/9 v/v.
###end p 27
###begin p 28
Plasma activity of antithrombin III and protein S were evaluated with commercial kits (Bhoeringer, Germany) as was plasma protein S activity (Biopool, Sweden).
###end p 28
###begin p 29
Anticardiolipin antibodies Ig G and IgM were detected by an ELISA method (anticariolipine Bouty, Italy).
###end p 29
###begin p 30
Lupus anticoagulant assays were performed using a DRVVT kit (Screen and Confirm, Gradipore, North Ryde, Australia) and according to the recommendations of the International Society of Thrombosis and Haemostasis.
###end p 30
###begin title 31
Control group
###end title 31
###begin p 32
###xml 88 96 <span type="species:ncbi:9606">patients</span>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
Seventy-five healthy age-matched subjects were enrolled as a control group. We included patients with one or more successful pregnancy and without gestational complication (intrauterine growth restriction, stillbirth, and abruptio placentae) or any abortion. We excluded patients with previous arterial and/or venous thrombosis. We also excluded subjects with first degree parents affected by arterial and/or venous thrombosis before than 65 years old.
###end p 32
###begin title 33
Statistical analysis
###end title 33
###begin p 34
Statistical analysis was based on Pearson chi-square (Npar tests); differences were considered to be significant if p < 0.05.
###end p 34
###begin title 35
Results
###end title 35
###begin p 36
###xml 66 73 66 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2-btt-2-897">Table 2</xref>
###xml 75 83 <span type="species:ncbi:9606">Patients</span>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
###xml 269 277 <span type="species:ncbi:9606">patients</span>
###xml 328 336 <span type="species:ncbi:9606">Patients</span>
The characteristics of study and control groups are summarised in Table 2. Patients were well matched according to age. Ninety patients showed alteration of hemostasis with a trend toward thrombophilia. Eighty-three patients with 2 or more early pregnancy losses and 7 patients with 1 or more late pregnancy loss were enrolled. Patients with RPL showed more gestations (median 3.1 vs 1.7 of control group), although only 10% ended with delivery of a living neonate.
###end p 36
###begin p 37
###xml 36 44 <span type="species:ncbi:9606">patients</span>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
Thrombophilia was present in 90/115 patients (78%) of study group compared with 12/75 (16%) of control subjects (p < 0.001, significant, s). Eighty-four patients showed isolated hemostatic abnormalities with a trend toward hypercoagulable state, while 6 patents showed combined defects inducing a hypercoagulable state, too.
###end p 37
###begin p 38
###xml 332 339 332 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2-btt-2-897">Table 2</xref>
###xml 599 606 599 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2-btt-2-897">Table 2</xref>
###xml 129 137 <span type="species:ncbi:9606">patients</span>
###xml 405 413 <span type="species:ncbi:9606">patients</span>
###xml 664 672 <span type="species:ncbi:9606">patients</span>
The evaluation of the analyzed thrombophilic conditions revealed that factor V Leiden heterozygosity was present in 6/115 (5.2%) patients with RPL vs 1/75 (1.3%) subjects of control group (p 0.091, ns); factor V Leiden homozygosity was absent in both study and control groups (statistical analysis not performed) (data not shown in Table 2). Prothrombin A20210G heterozygosity was present in 18/115 (15%) patients with RPL vs 2/75 (2.6%) control (p 0.001, s), while prothrombin A20210G homozigosity was absent both in study and control groups (statistical analysis not performed) (data not shown in Table 2). MTHFR C677T homozygosity was present in 35/115 (30.0%) patients with RPL vs 7/75 (9.3%) control (p: 0.001, s).
###end p 38
###begin p 39
###xml 134 141 134 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2-btt-2-897">Table 2</xref>
###xml 161 169 <span type="species:ncbi:9606">patients</span>
###xml 299 307 <span type="species:ncbi:9606">patients</span>
We did not find any subjects with antithrombin III deficiency in either group (statistical analysis not performed) (data not shown in Table 2). Yet 2/115 (1.7%) patients with RPL showed protein C deficiency vs no control subjects (p 0.194, ns). Protein S deficiency was present in 15/115 (13.0%) of patients with RPL vs 2/75 (2.6%) subjects of control subjects (p 0.003, s).
###end p 39
###begin p 40
###xml 70 75 <span type="species:ncbi:9606">women</span>
We also analyzed combined thrombophilic defects in our population. Of women affected by RPL, 6/115 (5.2%) showed combined thrombophilic defects compared with no control subjects (p 0.023, s). Analysis of combined thrombophilia underlined these combined defects: 2 subjects showed protein S deficiency associated with MTHFR C677T homozygosity, 2 subjects showed protein S deficiency associated with prothrombin A20210G heterozygosity, 1 subject showed MTHFR C677T homozygosity associated with prothrombin A20210G heterozygosity, and 1 subject showed factor V Leiden heterozigosity associated with prothrombin A20210G heterozygosity.
###end p 40
###begin p 41
###xml 99 104 <span type="species:ncbi:9606">women</span>
Acquired thrombophilia owing to antiphospolipid syndrome was detected in 10/115 (8.6%) study group women compared with no control subjects (p 0.003, s). LAC was present alone in 4/115 (3.4%) study group subjects; anticardiolipin antibodies (ie, IgG and/or IgM) were present alone in 4/115 (3.4%) study group subjects. LAC and anticardiolipin antibodies were both present in 2/115 study group subjects (1.7%).
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 396 416 396 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32-btt-2-897">Robertson et al 2006</xref>
###xml 609 625 609 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36-btt-2-897">Sarig et al 2002</xref>
###xml 249 257 <span type="species:ncbi:9606">patients</span>
###xml 377 385 <span type="species:ncbi:9606">patients</span>
###xml 752 757 <span type="species:ncbi:9606">women</span>
###xml 867 875 <span type="species:ncbi:9606">patients</span>
Alteration of hemostasis with a trend toward thrombophilia has been frequently associated to RPL. Several published studies seem to differ not only on the frequency of specific alteration but also on the inclusion and exclusion criteria of enrolled patients. For this reason we may observe also great differences about the involvement of thrombophilia during the evaluation of patients with RPL (Robertson et al 2006). However, the incidence of thrombophilia seems to increase if any causes of miscarriage, such as endocrine alterations and uterine malformations, are also excluded from the study population (Sarig et al 2002). Our data confirmed this trend and showed a strong association, reaching nearly 78%, of one or more thrombophilic defects in women with RPL if other common causes of miscarriage are excluded. Before evaluating thrombophilia in our selected patients, we excluded several conditions associated with miscarriage such as uterine malformation, anovulation, tube patency, endocrine diseases (ie, diabetes, hypothyroidism, hypopituitarism, hyperprolactinemia, luteal insufficiency, and PCOS), chronic and/or infectious diseases, and karyotype alterations.
###end p 43
###begin p 44
###xml 574 592 574 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21-btt-2-897">Ioannou et al 2000</xref>
###xml 594 614 594 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33-btt-2-897">Rosendaal et al 1998</xref>
###xml 616 632 616 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36-btt-2-897">Sarig et al 2002</xref>
###xml 634 653 634 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42-btt-2-897">Zalavras et al 2003</xref>
###xml 1368 1378 1368 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34-btt-2-897">Rozen 2001</xref>
###xml 1741 1761 1741 1761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-btt-2-897">Andersson et al 1992</xref>
###xml 1763 1782 1763 1782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-btt-2-897">Bonnette et al 1998</xref>
###xml 1820 1840 1820 1840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37-btt-2-897">Smithells et al 1980</xref>
###xml 842 850 <span type="species:ncbi:9606">patients</span>
Our data are also of interest if the frequency of specific thrombophilic defects is analyzed. We did not find a strong association with factor V Leiden gene polymorphism and RPL, while we did find an increased frequency of prothrombin A20210G gene polymorphism compared with control subjects and also with other studies. Our data for prothrombin A20210G gene polymorphism was statistically significant. However, these differences from previous studies may be linked also to ethnic background, according to published data on geographical distribution of these gene variants (Ioannou et al 2000; Rosendaal et al 1998; Sarig et al 2002; Zalavras et al 2003). This reason may also explain the strong impact of the homozygosity of the MTHFR C677T gene polymorphism, which is present in the homozygosity gene variants in nearly 30% of the enrolled patients. Although MTFHR C677T gene polymorphism is a well recognized thrombotic risk factor, in particular for venous thromboembolism, data on its role in the pathophysiology of RPL per se is still a matter of discussion because of the role of folic acid in homocysteine metabolism. From another point of view, the relevant incidence of the MTHFR C677T gene variant may also be due to ethnic background, and for this reason we may also observe an increased incidence of the TT genotype in the control group (ie, nearly 16%) (Rozen 2001). However, from a metabolic point of view previous studies may underestimate the involvement of homocysteine metabolism and MTHFR C677T gene variants in RPL: usually MTHFR C677T gene variants are analyzed only if a thrombotic disease, such as RPL, is associated with hyperhomocysteinemia. Yet the role of folic acid fortification during pregnancy is well known (Andersson et al 1992; Bonnette et al 1998) for preventing neural tube defects (Smithells et al 1980), and this folic acid fortification may determine also a transient reduction in homocysteine levels during pregnancy.
###end p 44
###begin p 45
###xml 277 295 277 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36-btt-2-897">Sarig et al (2002)</xref>
We did not find in our population homozygosity for prothrombin A20210G or factor V Leiden gene polymorphisms, or antithrombin deficiency. However, we did find a low incidence of protein C deficiency in our population, and these data seem to be in agreement with the results of Sarig et al (2002).
###end p 45
###begin p 46
###xml 242 259 242 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35-btt-2-897">Sanson et al 1996</xref>
###xml 261 277 261 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36-btt-2-897">Sarig et al 2002</xref>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
An increased frequency (statistically significant) of protein S deficiency was also found in our population, highlighting again its relevance in these patients affected by RPL. These data are also in agreement with those previously reported (Sanson et al 1996; Sarig et al 2002).
###end p 46
###begin p 47
###xml 166 182 166 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36-btt-2-897">Sarig et al 2002</xref>
###xml 94 99 <span type="species:ncbi:9606">women</span>
We found also a statistically significant increased incidence of antiphospholipid syndrome in women with RPL compared with control, which agrees with published data (Sarig et al 2002).
###end p 47
###begin p 48
###xml 347 362 347 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18-btt-2-897">Gris et al 1999</xref>
###xml 364 385 364 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38-btt-2-897">Sotiriadis et al 2007</xref>
###xml 81 86 <span type="species:ncbi:9606">women</span>
###xml 138 143 <span type="species:ncbi:9606">women</span>
###xml 315 320 <span type="species:ncbi:9606">women</span>
###xml 426 434 <span type="species:ncbi:9606">patients</span>
###xml 597 602 <span type="species:ncbi:9606">women</span>
###xml 687 695 <span type="species:ncbi:9606">patients</span>
###xml 751 756 <span type="species:ncbi:9606">women</span>
Particular attention should also be paid to the incidence of combined defects in women with RPL, which reached nearly 10% of investigated women. This observation could be very interesting for future studies because previous case control studies have underlined a potential role of combined thrombophilic defects in women with late pregnancy loss (Gris et al 1999; Sotiriadis et al 2007). We observed that more than 60% of our patients showed not only late pregnancy loss, as already reported in the literature, but also early RPL. Because our data on the role of combined thrombophilic defects in women with RPL reach statistical significance, even though the reduced number of selected patients was few, the role of combined thrombophilic defects in women with any type of recurrent pregnancy should be analyzed in further studies.
###end p 48
###begin p 49
###xml 49 54 <span type="species:ncbi:9606">women</span>
###xml 301 309 <span type="species:ncbi:9606">patients</span>
###xml 421 426 <span type="species:ncbi:9606">women</span>
###xml 903 911 <span type="species:ncbi:9606">patients</span>
Our data emphasizes the role of thrombophilia in women with RPL. Specific research on the alteration of hemostasis in this clinical setting is particularly relevant in order to establish a possible protocol that supports clinical surveillance and follow up associated with thromboprophylaxis of these patients, both for repeated pregnancy loss and deep venous thrombosis, which is still a common complication in pregnant women. For the frequency of thrombophilic defects, we confirmed a major role for protein S deficiency, antiphospholipid syndrome, prothrombin A20210G gene variants, and MTHFR C677T gene variants, which has been reported previously. Interestingly, our data differ from those previously published in terms a reduced frequency of factor V Leiden gene variant. However, this gene variant should be also considered in this clinical setting because it has been observed in several of our patients, although its frequency did not reach statistical significance, probably because of a different ethnic distribution in our geographical area.
###end p 49
###begin p 50
###xml 231 250 231 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12-btt-2-897">Di Micco et al 2004</xref>
###xml 397 416 397 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6-btt-2-897">Brenner et al 2005a</xref>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5-btt-2-897">b</xref>
###xml 421 442 421 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39-btt-2-897">Stephenson et al 2004</xref>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
###xml 315 320 <span type="species:ncbi:9606">women</span>
###xml 696 701 <span type="species:ncbi:9606">women</span>
Alteration of hemostasis with a trend toward hypercoagulable state should be evaluated soon if patients affected by RPL do not show other causes of miscarriage. Because such patients may show an asymptomatic hyperocagulable state (Di Micco et al 2004) and because antithrombotic treatment in thrombophilic pregnant women with previous RPL has been shown to improve prognosis of related pregnancy (Brenner et al 2005a, b; Stephenson et al 2004), the possibility of starting early antithrombotic treatment (ie, before the beginning of pregnancy) should be studied, based on aspirin and/or low-molecular-weight heparin in order to evaluate further improvements in pregnancy outcome of thrombophilic women.
###end p 50
###begin p 51
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Disclosures</bold>
Disclosures
###end p 51
###begin p 52
The authors have no conflicts of interest to declare.
###end p 52
###begin title 53
References
###end title 53
###begin article-title 54
Decreased serum homocysteine in pregnancy
###end article-title 54
###begin article-title 55
"Primary", "secondary" and other variants of antiphospholipid syndrome"
###end article-title 55
###begin article-title 56
###xml 67 72 <span type="species:ncbi:9606">women</span>
Plasma homocyst(e)ine concentrantions in pregnant and non pregnant women with controlled folate intake
###end article-title 56
###begin article-title 57
###xml 35 40 <span type="species:ncbi:9606">women</span>
Factor XII (Hageman) deficiency in women with abitual abortion: new subpopulation of recurrent aborters?
###end article-title 57
###begin article-title 58
###xml 50 55 <span type="species:ncbi:9606">women</span>
Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX Study
###end article-title 58
###begin article-title 59
###xml 50 55 <span type="species:ncbi:9606">women</span>
Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study
###end article-title 59
###begin article-title 60
###xml 42 47 <span type="species:ncbi:9606">women</span>
Thrombophilic polymorphisms are common in women with fetal loss without apparent cause
###end article-title 60
###begin article-title 61
Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss
###end article-title 61
###begin article-title 62
The prevalence of antiphospholipid antibodies in cases of recurrent pregnancy loss
###end article-title 62
###begin article-title 63
###xml 36 41 <span type="species:ncbi:9606">woman</span>
Acquired factor XII deficiency in a woman with recurrent pregnancy loss: working on a differential diagnosis in a single case
###end article-title 63
###begin article-title 64
###xml 41 46 <span type="species:ncbi:9606">women</span>
Study of lupus anticoagulant in pregnant women with recurrent abortion
###end article-title 64
###begin article-title 65
###xml 56 61 <span type="species:ncbi:9606">women</span>
The role of d-dimer as first marker of thrombophilia in women affected by sterility: implications in pathophysiology and diagnosis of thrombophilia-induced sterility
###end article-title 65
###begin article-title 66
Elevated coagulation factor VIII and the risk for maternal early pregnancy loss
###end article-title 66
###begin article-title 67
Angiotensin convertine enzyme DD genotype, angiotensin - receptor CC genotype, and hyperhomocysteinemia increase first-trimester fetal-loss susceptibility
###end article-title 67
###begin article-title 68
Prevalence of factor V G1691A (factor V-Leiden) and prothrombin G20210A gene mutations in a recurrent miscarriage population
###end article-title 68
###begin article-title 69
Factor V Leiden is associated with repeated and recurrent unexplained fetal losses
###end article-title 69
###begin article-title 70
Thrombophilia: implications for pregnancy outcome
###end article-title 70
###begin article-title 71
###xml 182 183 182 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
Case control study of the frequency of thrombophilic disorders in couple with late pregnancy loss and no thrombotic antecedent. The Nimes Obstetricians and Haematologists Study (NOHA5)
###end article-title 71
###begin article-title 72
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Anticardiolipin antibody and anti-cardiolipin beta-2-glycoprotein I antibody in patients with recurrent fetal miscarriage
###end article-title 72
###begin article-title 73
Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study
###end article-title 73
###begin article-title 74
The prevalence of factor V Leiden as a risk factor for venous thromboembolism in the population of North-Western Greece
###end article-title 74
###begin article-title 75
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Antibodies to factor XII and recurrent fetal loss in patients with the anti-antiphospholid syndrome
###end article-title 75
###begin article-title 76
Polymorphism for mutation of cytosine to thymine at location 677 in the methylenetetrahydrofolate reductase gene is associated with recurrent early fetal loss
###end article-title 76
###begin article-title 77
###xml 36 41 <span type="species:ncbi:9606">women</span>
Mutations in coagulation factors in women with unexplained late fetal loss
###end article-title 77
###begin article-title 78
Recurrent early pregnancy loss and genetic-related distrubances in folate and homocysteine metabolism
###end article-title 78
###begin article-title 79
Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low molecular weight heparin versus unfractioned heparin
###end article-title 79
###begin article-title 80
###xml 78 83 <span type="species:ncbi:9606">women</span>
Pregnancy associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden
###end article-title 80
###begin article-title 81
G20210A prothrombin gene mutation: prevalence in a recurrent miscarriage population
###end article-title 81
###begin article-title 82
Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester
###end article-title 82
###begin article-title 83
###xml 71 76 <span type="species:ncbi:9606">women</span>
Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage
###end article-title 83
###begin article-title 84
Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage
###end article-title 84
###begin article-title 85
The Thrombosis: risk and assessment of thrombophilia screening (TREATS) study. Thrombophilia in pregnancy: a systematic review
###end article-title 85
###begin article-title 86
Geographic distribution of the 20210 G to A prothrombin variant
###end article-title 86
###begin article-title 87
Polymorphisms of folate and cobalamine metabolism
###end article-title 87
###begin article-title 88
###xml 89 94 <span type="species:ncbi:9606">women</span>
The risk of abortion and stillbirth in antithrombin-, protein C, and protein S deficient women
###end article-title 88
###begin article-title 89
###xml 27 32 <span type="species:ncbi:9606">women</span>
Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage
###end article-title 89
###begin article-title 90
Possible prevention of neural tube defects by periconceptional vitamin supplementation
###end article-title 90
###begin article-title 91
###xml 36 41 <span type="species:ncbi:9606">women</span>
Combined thrombophilic mutations in women with unexplained recurrent miscarriage
###end article-title 91
###begin article-title 92
Treatment of antiphospholipid syndrome (APS) in pregnancy: a randomised pilot trial comparing low molecular weight heparin to unfractioned heparin
###end article-title 92
###begin article-title 93
###xml 39 44 <span type="species:ncbi:9606">women</span>
Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss
###end article-title 93
###begin article-title 94
Activated protein C resistance and factor V Leiden mutation can be associated with first- as well as secondtrimester recurrent pregnancy loss
###end article-title 94
###begin article-title 95
Prevalence of the G20210A prothrombin gene mutation in Northwestern Greece and association with venous thromboembolism
###end article-title 95
###begin p 96
Inclusion and exclusion criteria of selected subjects
###end p 96
###begin p 97
###xml 0 13 0 13 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviation:</bold>
Abbreviation: PCOS, polycystic ovarian syndrome.
###end p 97
###begin p 98
###xml 42 47 <span type="species:ncbi:9606">women</span>
Frequency of thrombophilic alterations in women with RPL without other causes of miscarriage and control group
###end p 98
###begin p 99
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: RPL, recurrent pregnangy loss; MTHFR C677T, methylene tetrahydro folate reductase gene polymorphism; FVL, factor V Leiden gene polymorphism; PTHR A20210G, prothrombin gene polymorphism; PS, protein S deficiency; PC, protein C deficiency; APS, antiphospholipid syndrome.
###end p 99

